PMID- 33068935
OWN - NLM
STAT- MEDLINE
DCOM- 20210219
LR  - 20210219
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 132
DP  - 2020 Dec
TI  - The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors 
      therapy for advanced hepatocellular carcinoma.
PG  - 110797
LID - S0753-3322(20)30990-2 [pii]
LID - 10.1016/j.biopha.2020.110797 [doi]
AB  - China has one of the highest incidence rates of hepatocellular carcinoma (HCC) in 
      the world. As most patients are diagnosed with advanced or unretractable HCC, 
      systematic therapy is still the main treatment method for HCC. Currently, 
      tyrosine kinase inhibitors (TKIs) and Immune checkpoint inhibitors (ICIs) are 
      both the chief systematic therapy. And some studies have shown that the 
      combination of TKIs and ICIs is more effective than monotherapy. The purpose of 
      this review is to outline the rationale for the combination between lenvatinib 
      and anti-PD-1(programmed cell death 1) and clinical trials to support this 
      "golden combination". We also discuss the commonly treatment-emergent adverse 
      events (AEs) and solutions for the patients with HCC who received the combination 
      between lenvatinib and anti-PD-1 antibodies. Finally, we focus on the novel 
      approaches, future perspectives and potential challenges about the combination of 
      TKIs and ICIs.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Masson SAS.. All rights 
      reserved.
FAU - Wang, Yun
AU  - Wang Y
AD  - Hospital of Qingdao University, Qingdao, China.
FAU - Jiang, Man
AU  - Jiang M
AD  - Hospital of Qingdao University, Qingdao, China.
FAU - Zhu, Jingjuan
AU  - Zhu J
AD  - Hospital of Qingdao University, Qingdao, China.
FAU - Qu, Jialin
AU  - Qu J
AD  - Hospital of Qingdao University, Qingdao, China.
FAU - Qin, Kang
AU  - Qin K
AD  - Hospital of Qingdao University, Qingdao, China.
FAU - Zhao, Deze
AU  - Zhao D
AD  - Hospital of Qingdao University, Qingdao, China.
FAU - Wang, Li
AU  - Wang L
AD  - Hospital of Qingdao University, Qingdao, China.
FAU - Dong, Lina
AU  - Dong L
AD  - Hospital of Qingdao University, Qingdao, China.
FAU - Zhang, Xiaochun
AU  - Zhang X
AD  - Hospital of Qingdao University, Qingdao, China. Electronic address: 
      zhangxiaochun9670@126.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201014
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Quinolines)
RN  - EE083865G2 (lenvatinib)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse 
      effects/pharmacology
MH  - Carcinoma, Hepatocellular/*drug therapy/pathology
MH  - Humans
MH  - Immune Checkpoint Inhibitors/administration & dosage
MH  - Liver Neoplasms/*drug therapy/pathology
MH  - Phenylurea Compounds/administration & dosage
MH  - Protein Kinase Inhibitors/administration & dosage
MH  - Quinolines/administration & dosage
OTO - NOTNLM
OT  - Hepatocellular carcinoma
OT  - Immune checkpoint therapy
OT  - Lenvatinib
OT  - Nivolumab
OT  - Pembrolizumab
EDAT- 2020/10/18 06:00
MHDA- 2021/02/20 06:00
CRDT- 2020/10/17 20:12
PHST- 2020/07/15 00:00 [received]
PHST- 2020/09/11 00:00 [revised]
PHST- 2020/09/17 00:00 [accepted]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2021/02/20 06:00 [medline]
PHST- 2020/10/17 20:12 [entrez]
AID - S0753-3322(20)30990-2 [pii]
AID - 10.1016/j.biopha.2020.110797 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2020 Dec;132:110797. doi: 10.1016/j.biopha.2020.110797. Epub 
      2020 Oct 14.